ArticleBMC cardiovascular disorders2025
Global burden of myocarditis in adolescents and young adults, 1990-2019.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
BACKGROUND AND
objectiveEarly myocarditis has increased the risk of heart failure, arrhythmias, and sudden cardiac death. We aimed to estimate the global burden of myocarditis in adolescents and young adults from 1990 to 2019.
methodsWe analysed incident cases and the age-standardized rates of incidence, death, and disability-adjusted life years (DALYS) of myocarditis in 204 countries and territories from 1990 to 2019 in young people (aged 15-39) from the Global Burden of Disease Study stratified by age and sex. Predictions up to 2030 were obtained via Norpred analysis.
resultsIn 2019, the global number of myocarditis incident cases in adolescents and young adults increased to 1,265,800, with a 62.2% increase from 1990. The global incidence rate declined from 16.74 per 100,000 population in 1990 to 16.00 in 2019. From 1990 to 2019, the high sociodemographic index regions presented the highest estimated annual percentage change in incidence (-0.41, 95% CI= -0.49 to -0.34). In 2019, the ASDR was 15.81 (95% CI = 14.92 to 16.56), with the middle sociodemographic index quintile being the highest contributor (73,671.19 DALYs). The incidence, mortality, and DALYs of myocarditis will be stable or decrease from 2020 to 3030. Males had higher levels of the above indicators than females.
conclusionWhile the total number of cases has grown globally in the past three-decades, the incidence rate of myocarditis has declined, with the burden disproportionately affecting males and middle-SDI populations, which highlights the need for targeted prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.